Abstract:Topic: 25. Gene therapy, cellular immunotherapy and vaccination - Clinical Background: Neutropenia and cytokine release syndrome (CRS) are two major toxicities of Chimeric antigen receptor T (CAR T) cell therapy. Granulocyte-macrophage colony-stimulating factor (GM-CSF) is an ideal candidate treatment for neutropenia except for its potential aggravation of CRS. We hypothesized that the optimal timing of supplemental with GM-CSF in a shortage of host immunity and CAR T-cell was chosen as avoidance of CRS. Aims: We explored GM-CSF as a therapeutic intervention aimed at alleviating neutropenia, promoting cellular immunity recovery, as well as enhancing CAR T-cell expansion in patients. In this cohort, nine patients undergone different CAR T-cell therapies have been treated with GM-CSF, to assess the safety and efficacy of GM-CSF intervention post-CAR T-cell therapy while circulating CAR T-cell declined. Methods: Nine patients were enrolled in cohort from July 2021 and November 2021 to receive GM-CSF therapy whose clinical characteristics are shown in Table 1. GM-CSF was subcutaneous administrated. The indication for initiation of GM-CSF therapy was patients who display moderate neutropenia with absolute neutrophil counts (ANC) <1500 cells/mm3. The indication for termination of GM-CSF therapy, was either when their ANC levels had reached to 3000-5000 cells/mm3. All patients started GM-CSF at 100ug daily. After 3 days, the dose of GM-CSF in two patients was escalated to 200ug daily because no increment in WBC was observed. Results: The median duration of GM-CSF intervention was 15 days (4-30). The median interval between start of GM-CSF and CAR T-cell infusion was 20 days (8-126) while the number of CAR T-cell in peripheral blood (PB) dropped to 20.3% (0-59.7) of pre-GM-CSF peak except for patient #2 who had no CAR T-cell expansion before GM-CSF administration. The median duration of GM-CSF intervention was 15 days (4-30). Seven out of nine patients (77.8%) experienced CAR T-cell expansion in PB during GM-CSF usage. The median baseline and peak CAR T cells count in PB of the seven patients with CAR T-cell expansion were 0.85×106/L (0-50.9) and 6.06×106/L (1.43-112.55). The peaks of CAR T-cell levels appeared in day 7(2-11) following the initiation of GM-CSF administration with increases of 2.84×106/L (0.38-61.65). In addition, although no increased CAR T-cell count in PB was observed in patients #8 and #9, the percentage of CAR T-cell in cerebrospinal fluid of patient #8 increased from 4.43% to 35.78% at day 6 and dropped to 1.38% at day 10 meanwhile GM-CSF was administrated. Also, increased white blood cells in PB was observed in all patients. The median onset and duration time of WBC recovery were 9 (1-14) and 17(3-53) days. Moreover, the increment of WBC, neutrophil, lymphocyte and CD3-CD16+CD56+ natural killer cell in PB was observed. In addition, no CRS or fatal infection occurred during GM-CSF treatment. Summary/Conclusion: Overall, we explored the timing of GM-CSF administration to play a role in CAR T-cell expansion and cellular immunity recovery without inducing CRS which facilitates to increase durable complete responses and decrease infection rates after CAR T therapy. On the basis of these results, this approach may improve the overall safety and efficacy of CAR T therapies for cancer patients and may eliminate the need for robust anti-infection treatment. Therefore, this study provides evidence for the clinical feasibility of combining CAR T-cell therapy with the GM-CSF to treat neutropenia patients with concomitant declination of circulating CAR T-cell.Keywords: CAR-T, Cytokine release syndrome, Neutropenia, Infection

Associations of granulocyte colony-stimulating factor with toxicities and efficacy of chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell acute lymphoblastic leukemia

Associations of Granulocyte Colony-Stimulating Factor with Toxicities and Efficacy of Chimeric Antigen Receptor T-cell Therapy in Relapsed or Refractory Multiple Myeloma

Abstract 6327: Impact of G-CSF on safety and efficacy of CAR T-cell therapy in non-Hodgkin lymphoma

Effect of early granulocyte-colony-stimulating factor administration in the prevention of febrile neutropenia and impact on toxicity and efficacy of anti-CD19 CAR-T in patients with relapsed/refractory B-cell lymphoma

Correlation Analysis Between Levels of Inflammatory Cytokine in Peripheral Blood and Cytokine Release Syndrome in Patients with B-ALL after CAR-T Immunotherapy

Administration of Granulocyte-Macrophage Colony-Stimulating Factor Enhanced Chimeric Antigen Receptor T-cell Expansion and Cellular Immunity Recovery Without Inducing Cytokine Release Syndrome

The influence of CRS and ICANS on the efficacy of anti-CD19 CAR-T treatment for B-cell acute lymphoblastic leukemia

Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant

Pb2494: administration of granulocyte-macrophage colony-stimulating factor enhanced car t-cell expansion and cellular immunity recovery without inducing cytokine release syndrome

Investigation of the risk factors to predict cytokine release syndrome in relapsed or refractory B-cell acute lymphoblastic leukemia patients receiving IL-6 knocking down anti-CD19 chimeric antigen receptor T-cell therapy

A Multicenter Study of CAR-T Cell Therapy for Relapse of B-ALL Post Allogeneic Stem Cell Transplantation

Treatment Response, Survival, Safety, and Predictive Factors to Chimeric Antigen Receptor T Cell Therapy in Chinese Relapsed or Refractory B Cell Acute Lymphoblast Leukemia Patients

The severe cytokine release syndrome in phase I trials of CD19-CAR-T cell therapy: a systematic review

Factors associated with treatment response to CD19 CAR-T therapy among a large cohort of B cell acute lymphoblastic leukemia

Correlation of Cytokine Release Syndrome With Prognosis After Chimeric Antigen Receptor T Cell Therapy: Analysis of 54 Patients With Relapsed or Refractory Multiple Myeloma

Individual Patient Data Meta-Analysis from 16 Trials for Safety Factors in Cytokine Release Syndrome After CAR-T Therapy in Patients with Non-Hodgkin Lymphoma (NHL) and Acute Lymphoblastic Leukemia

Cytopenia after chimeric antigen receptor T cell immunotherapy in relapsed or refractory lymphoma

Efficacy and Safety of Children with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia after Anti-CD19 CAR T-Cell Therapy Without Bridging Transplantation.

Clinical Presentation, Management and Biomarkers of Cytokine Release Syndrome after Anti-CD19 CART-Cell Therapy for r/r ALL

Adverse Reactions in Relapsed/Refractory B-Cell Lymphoma Administered with Chimeric Antigen Receptor T Cell Alone or in Combination with Autologous Stem Cell Transplantation

[Clinical analysis of long-term survival and influencing factors of chimeric antigen receptor T-cell therapy in relapsed/refractory acute B-cell lymphoblastic leukemia].